Peptides in atherosclerosis nanomedicine provide structural, targeting, and therapeutic functionality and can assist in overcoming delivery barriers of traditional pharmaceuticals. Moreover, their inherent biocompatibility and biodegradability make them especially attractive as materials intended for use in vivo. In this review, an overview of nanoparticle-associated targeting and therapeutic peptides for atherosclerosis is provided, including peptides designed for cellular targets such as endothelial cells, monocytes, and macrophages as well as for plaque components such as collagen and fibrin. An emphasis is placed on recent advances in multimodal strategies and a discussion on current challenges and barriers for clinical applicability is presented.
MozaffarianDBenjaminEJGoASArnettDKBlahaMJCushmanMde FerrantiSDesprésJPFullertonHJHowardVJHuffmanMDJuddSEKisselaBMLacklandDTLichtmanJHLisabethLDLiuSMackeyRHMatcharDBMcGuireDKMohlerERMoyCSMuntnerPMussolinoMENasirKNeumarRWNicholGPalaniappanLPandeyDKReevesMJRodriguezCJSorliePDSteinJTowfighiATuranTNViraniSSWilleyJZWooDYehRWTurnerMB. Heart disease and stroke statistics—2015 update: a report from the American heart association. Circulation2014; 129: e28–292.
2.
National Heart Lung Blood Institute. What is atherosclerosis? National Institute of Health, Bethesda, MD, 2015.
3.
Staff MC. Arteriosclerosis/atherosclerosis. Mayo Clinic, Mayo Foundation for Medical Education and Research, Rochester, MN, 1998–2015.
4.
American Heart Association. What is cardiovascular disease? American Heart Association, Inc, Dallas, TX, 2014.
5.
ChungEJTirrellM. Recent advances in targeted, self-assembling nanoparticles to address vascular damage due to atherosclerosis. Adv Healthcare Mat2015; 4: 2408–22.
6.
LibbyPRidkerPMMaseriA. Inflammation and atherosclerosis. Circulation2002; 105: 1135–43.
7.
WesteinEFlierlUHagemeyerCEPeterK. Destination known: targeted drug delivery in atherosclerosis and thrombosis. Drug Dev Res2013; 74: 460–71.
8.
WilsonHM. Macrophages heterogeneity in atherosclerosis—implications for therapy. J Cell Mol Med2010; 14: 2055–65.
9.
MoghimiSMHunterACMurrayJC. Nanomedicine: current status and future prospects. FASEB2005; 19: 311–30.
10.
UzielyBJeffersSIsacsonRKutschKWei-TsaoDYehoshuaZLibsonEMuggiaFMGabizonA. Liposomal doxorubicin: antitumor activity and unique toxicities during two complementary phase I studies. J Clin Oncol1995; 13: 1777–85.
11.
RahaSPauneskuTWoloschakG. Peptide-mediated cancer targeting of nanoconjugates. Wiley Interdiscip Rev Nanomed Nanobiotechnol2011; 3: 269–81.
12.
WebberMJKesslerJAStuppSI. Emerging peptide nanomedicine to regenerate tissues and organs. J Internal Med2010; 267: 71–88.
13.
HowardMDHoodEDZernBShuvaevVVGrosserTMuzykantovVR. Nanocarriers for vascular delivery of anti-inflammatory agents. Annual Rev Pharm Toxicol2014; 54: 205–26.
14.
ChackoAMHoodEDZernBJMuzykantovVR. Targeted nanocarriers for imaging and therapy of vascular inflammation. Curr Opin Coll Interf Sci2011; 16: 215–27.
15.
SchienerMHossannMViolaJROrtega-GomezAWeberCLauberKLindnerLHSoehnleinO. Nanomedicine-based strategies for treatment of atherosclerosis. Trends Mol Med2014; 20: 271–81.
16.
LewisDRKamisogluKYorkAWMoghePV. Polymer-based therapeutics: nanoassemblies and nanoparticles for management of atherosclerosis. Wiley Interdiscip Rev Nanomed Nanobiotechnol2011; 3: 400–20.
17.
LobattoMEFusterVFayadZAMulderWJM. Perspectives and opportunities for nanomedicine in the management of atherosclerosis. Nat Rev Drug Discov2011; 10: 835–52.
18.
PsarrosCLeeRMargaritisMAntoniadesC. Nanomedicine for the prevention, treatment and imaging of atherosclerosis. Maturitas2012; 73: 52–60.
19.
KanwarRKChaudharyRTsuzukiTKanwarJR. Emerging engineered magnetic nanoparticulate probes for molecular MRI of atherosclerosis: how far have we come?Nanomedicine2012; 7: 899–916.
20.
WicklineSANeubauerAMWinterPMCaruthersSDLanzaGM. Molecular imaging and therapy of atherosclerosis with targeted nanoparticles. J Mag Res Imag2007; 25: 667–80.
21.
ErasoLHReillyMPSehgalCMohlerER. Emerging diagnostic and therapeutic molecular imaging applications in vascular disease. Vasc Med2011; 16: 145–56.
SrinivasanRMarchantREGuptaAS. In vitro and in vivo platelet targeting by cyclic RGD-modified liposomes. JBMR A2010; 93: 1004–15.
24.
BruckmanMAJiangKSimpsonEJRandolphLNLuytLGYuXSteinmetzNF. Dual-modal magnetic resonance and fluorescence imaging of atherosclerotic plaques in vivo using VCAM-1 targeted tobacco mosaic virus. Nano Lett2014; 14: 1551–8.
25.
ChungEJMlinarLBNordKSugimotoMJWonderEAlenghatFJFangYTirrellM. Monocyte-targeting supramolecular micellar assemblies: a molecular diagnostic tool for atherosclerosis. Adv Healthc Mat2015; 4: 367–76.
26.
KellyKNahrendorfMYuAReynoldsFWeisslederR. In vivo phage display selection yields atherosclerotic plaque targeted peptides for imaging. Mol Imaging Bio2006; 8: 201–7.
27.
KusunoseJZhangHGagnonMKPanTSimonSFerraraK. Microfluidic system for facilitated quantification of nanoparticle accumulation to cells under laminar flow. Ann Biomed Eng2013; 41: 89–99.
28.
KusunoseJGagnonMKJSeoJWFerraraKW. Quantitation of nanoparticle accumulation in flow using optimized microfluidic chambers. J Drug Target2014; 22: 48–56.
29.
KuoC-HLeonLChungEJHuangR-TSontagTJReardonCAGetzGSTirrellMFangY. Inhibition of atherosclerosis-promoting microRNAs via targeted polyelectrolyte complex micelles. J Mat Chem B2014; 2: 8142–53.
30.
NahrendorfMJafferFAKellyKASosnovikDEAikawaELibbyPWeisslederR. Noninvasive vascular cell adhesion molecule-1 imaging identifies inflammatory activation of cells in atherosclerosis. Circulation2006; 114: 1504–11.
31.
MlinarLBChungEJWonderEATirrellM. Active targeting of early and mid-stage atherosclerotic plaques using self-assembled peptide amphiphile micelles. Biomaterials2014; 35: 8678–86.
32.
SouthworthRKanedaMChenJZhangLZhangHYangXRazaviRLanzaGWicklineSA. Renal vascular inflammation induced by Western diet in ApoE-null mice quantified by 19F NMR of VCAM-1 targeted nanobeacons. Nanomedicine2009; 5: 359–67.
33.
PanHMyersonJWHuLMarshJNHouKScottMJAllenJSHuGSan RomanSLanzaGMSchreiberRDSchlesingerPHWicklineSA. Programmable nanoparticle functionalization for in vivo targeting. FASEB J2013; 27: 255–64.
34.
KheirolomoomAKimCWSeoJWKumarSSonDJGagnonMKInghamESFerraraKWJoH. Multifunctional nanoparticles facilitate molecular targeting and miRNA delivery to inhibit atherosclerosis in ApoE–/– mice. ACS Nano2015; 9: 8885–97.
35.
KellyKAAllportJRTsourkasAShinde-PatilVRJosephsonLWeisslederR. Detection of vascular adhesion molecule-1 expression using a novel multimodal nanoparticle. Circulation Res2005; 96: 327–36.
36.
MichalskaMMachtoubLMantheyHDBauerEHeroldVKrohneGLykowskyGHildenbrandMKampfTJakobPZerneckeABauerWR. Visualization of vascular inflammation in the atherosclerotic mouse by ultrasmall superparamagnetic iron oxide vascular cell adhesion molecule-1–specific nanoparticles. Arterioscler Thromb Vasc Biol2012; 32: 2350–7.
37.
ParkKHongH-YMoonHJLeeBHKimISKwonICRheeK. A new atherosclerotic lesion probe based on hydrophobically modified chitosan nanoparticles functionalized by the atherosclerotic plaque targeted peptides. J Controll Release2008; 128: 217–23.
38.
LeeGYKimJ-HOhGTLeeB-HKwonICKimI-S. Molecular targeting of atherosclerotic plaques by a stabilin-2-specific peptide ligand. J Controll Release2011; 155: 211–7.
39.
LuehmannHPPresslyEDDeteringLWangCPierceRWoodardPKGroplerRJHawkerCJLiuY. PET/CT imaging of chemokine receptor CCR5 in vascular injury model using targeted nanoparticle. J Nucl Med2014; 55: 629–34.
40.
UchidaMKosugeHTerashimaMWillitsDALiepoldLOYoungMJMcConnellMVDouglasT. Protein cage nanoparticles bearing the LyP-1 peptide for enhanced imaging of macrophage-rich vascular lesions. ACS Nano2011; 5: 2493–502.
41.
ZhaoYBlackASBonnetDJMaryanoffBECurtissLKLemanLJGhadiriMR. In vivo efficacy of HDL-like nanolipid particles containing multivalent peptide mimetics of apolipoprotein A-I. J Lipid Res2014; 55: 2053–63.
42.
ZhaoYImuraTLemanLJCurtissLKMaryanoffBEGhadiriMR. Mimicry of high-density lipoprotein: functional peptide–lipid nanoparticles based on multivalent peptide constructs. J Am Chem Soc2013; 135: 13414–24.
43.
CormodeDPChandrasekarRDelshadABriley-SaeboKCCalcagnoCBarazzaAMulderWJFisherEAFayadZA. Comparison of synthetic high density lipoprotein (HDL) contrast agents for MR imaging of atherosclerosis. Bioconjug Chem2009; 20: 937–43.
44.
MarracheSDharS. Biodegradable synthetic high-density lipoprotein nanoparticles for atherosclerosis. Proc Natl Acad Sci U S A2013; 110: 9445–50.
45.
ChenWVucicELeupoldEMulderWJCormodeDPBriley-SaeboKCBarazzaAFisherEADatheMFayadZA. Incorporation of an apoE-derived lipopeptide in high-density lipoprotein MRI contrast agents for enhanced imaging of macrophages in atherosclerosis. Contrast Media Mol Imaging2008; 3: 233–42.
46.
ChenWCormodeDPVengrenyukYHerranzBFeigJEKlinkAMulderWJMFisherEAFayadZA. Collagen-specific peptide conjugated high density lipoprotein nanoparticles as MR contrast agents to evaluate compositional changes in murine atherosclerotic plaques under regression conditions. JACC Cardiovasc Imag2013; 6: 373–84.
47.
FredmanGKamalyNSpolituSMiltonJGhorpadeDChiassonRKuriakoseGPerrettiMFarokhzadOTabasI. Targeted nanoparticles containing the proresolving peptide Ac2-26 protect against advanced atherosclerosis in hypercholesterolemic mice. Sci Transl Med2015; 7: 275ra20–275ra20.
48.
Bandeira-MeloCBonavitaAGCDiazBLe SilvaPMRCarvalhoVFJosePJFlowerRJPerrettiMMartinsMA. A Novel effect for annexin 1-derived peptide Ac2-26: Reduction of allergic inflammation in the rat. J Pharm Exp Ther2005; 313: 1416–22.
49.
PetersDKastantinMKotamrajuVRKarmaliPPGujratyKTirrellMRuoslahtiE. Targeting atherosclerosis by using modular, multifunctional micelles. Proc Natl Acad Sci U S A2009; 106: 9815–9.
ChungEJPinedaFNordKKarczmarGLeeS-KTirrellM. Fibrin-targeting, peptide amphiphile micelles as contrast agents for MRI. J Cell Sci Ther2014; 5: 181–181.
52.
StarmansLWBurdinskiDHaexNPMoonenRPStrijkersGJNicolayKGrullH. Iron oxide nanoparticle-micelles (ION-micelles) for sensitive (molecular) magnetic particle imaging and magnetic resonance imaging. PLoS One2013; 8: e57335–e57335.
53.
FangYDaviesPF. Site-specific microRNA-92a regulation of Krüppel-like factors 4 and 2 in atherosusceptible endothelium. Arterioscler Thromb Vasc Biol2012; 32: 979–87.
54.
Najafi-ShoushtariSHKristoFLiYShiodaTCohenDEGersztenRENaarAM. MicroRNA-33 and the SREBP host genes cooperate to control cholesterol homeostasis. Science2010; 328: 1566–9.
55.
SwirskiFKPittetMJKircherMFAikawaEJafferFALibbyPWeisslederR. Monocyte accumulation in mouse atherogenesis is progressive and proportional to extent of disease. Proc Natl Acad Sci U S A2006; 103: 10340–5.
56.
KashiwagiMImanishiTTsujiokaHIkejimaHKuroiAOzakiYIshibashiKKomukaiKTanimotoTInoYKitabataHHirataKAkasakT. Association of monocyte subsets with vulnerability characteristics of coronary plaques as assessed by 64-slice multidetector computed tomography in patients with stable angina pectoris. Atherosclerosis2010; 212: 171–6.
NahrendorfMWatermanPThurberGGrovesKRajopadhyeMPanizziPMarinelliBAikawaEPittetMJSwirskiFKWeisslederR. Hybrid in vivo FMT-CT imaging of protease activity in atherosclerosis with customized nanosensors. Arterioscler Thromb Vasc Biol2009; 29: 1444–51.
59.
LaakkonenPÅkermanMEBiliranHYangMFerrerFKarpanenTHoffmanRRuoslahtiE. Antitumor activity of a homing peptide that targets tumor lymphatics and tumor cells. Proc Natl Acad Sci U S A2004; 101: 9381–6.
60.
DamianoMGMutharasanRKTripathySMcMahonKMThaxtonCS. Templated high density lipoprotein nanoparticles as potential therapies and for molecular delivery. Adv Drug Deliv Rev2013; 65: 649–62.
61.
JonasAPhillipsMCLipoprotein structure. In: VanceDEVE (ed). Biochemistry of lipids, lipoproteins and membranes, 5th ed. San Diego, CA: Elsevier, 2008, pp. 485–506.
62.
WilsonPWAbbottRDCastelliWP. High density lipoprotein cholesterol and mortality. The Framingham heart study. Arteriosclerosis1988; 8: 737–41.
63.
MaxfieldFRTabasI. Role of cholesterol and lipid organization in disease. Nature2005; 438: 612–21.
64.
ChamberlainAMFolsomARHeckbertSRRosamondWDCushmanM. High-density lipoprotein cholesterol and venous thromboembolism in the Longitudinal Investigation of Thromboembolism Etiology (LITE). Blood2008; 112: 2675–80.
65.
NavabMAnantharamaiahGMReddySTFogelmanAM. Apolipoprotein A-I mimetic peptides and their role in atherosclerosis prevention. Nat Clin Pract Cardiovasc Med2006; 3: 540–7.
66.
KamalyNFredmanGSubramanianMGaddeSPesicACheungLFayadZALangerRTabasIFarokhzadOC. Development and in vivo efficacy of targeted polymeric inflammation-resolving nanoparticles. Proc Natl Acad Sci U S A2013; 110: 6506–11.
67.
LaMD’AmicoMBandieraSDi FilippoCOlianiSMGavinsFNFlowerRJPerrettiM. Annexin 1 peptides protect against experimental myocardial ischemia-reperfusion: analysis of their mechanism of action. FASEB J2001; 15: 2247–56.
68.
StarmansLWMoonenRPAussems-CustersEDaemenMJAPStrijkersGJNicolayKGrullH. Evaluation of iron oxide nanoparticle micelles for magnetic particle imaging (MPI) of thrombosis. PLoS One2015; 10: e0119257–e0119257.
69.
BentzonJFFalkE. Atherosclerotic lesions in mouse and man: is it the same disease?Curr Opin Lipid2010; 21: 434–40.
